Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GHRS GH Research	$10.75 -2.6%	$11.80	$6.00 ▼ $20.50	$558.16M	0.94	164,312 shs	23,253 shs
IMCR Immunocore	$29.07 -2.0%	$30.05	$27.19 ▼ $66.00	$1.45B	0.79	440,088 shs	2,455 shs
NTLA Intellia Therapeutics	$6.89 -3.1%	$9.93	$6.75 ▼ $28.18	$715.92M	1.97	2.20 million shs	510,690 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GHRS GH Research	-0.27%	-14.36%	+8.88%	+57.57%	+3.47%
IMCR Immunocore	+0.30%	+0.10%	+1.02%	+0.58%	-54.35%
NTLA Intellia Therapeutics	-11.90%	-23.63%	-29.53%	-39.02%	-74.15%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GHRS GH Research	2.4753 of 5 stars	4.5	1.0	0.0	1.6	2.5	0.0
IMCR Immunocore	1.8969 of 5 stars	3.3	0.0	0.0	3.3	3.3	0.0
NTLA Intellia Therapeutics	4.4515 of 5 stars	4.3	1.0	4.7	1.8	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GHRS GH Research	3.00	Buy	$30.86	187.18% Upside
IMCR Immunocore	2.54	Moderate Buy	$65.64	125.83% Upside
NTLA Intellia Therapeutics	2.63	Moderate Buy	$37.56	445.07% Upside

Current Analyst Ratings Breakdown

Latest IMCR, GHRS, and NTLA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/13/2025	GHRS GH Research	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$32.00
3/12/2025	IMCR Immunocore	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$71.00 ➝ $71.00
3/12/2025	IMCR Immunocore	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00
3/7/2025	GHRS GH Research	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$31.00
3/7/2025	IMCR Immunocore	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight	$35.00 ➝ $35.00
3/5/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
3/4/2025	NTLA Intellia Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$90.00 ➝ $50.00
2/28/2025	IMCR Immunocore	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00
2/28/2025	NTLA Intellia Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$55.00 ➝ $26.00
2/28/2025	NTLA Intellia Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$12.00 ➝ $14.00
2/28/2025	NTLA Intellia Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$60.00 ➝ $50.00

(Data available from 4/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GHRS GH Research	N/A	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	$310.20M	4.69	N/A	N/A	$7.42 per share	3.92
NTLA Intellia Therapeutics	$57.88M	12.32	N/A	N/A	$11.73 per share	0.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GHRS GH Research	-$35.59M	-$0.75	N/A	N/A	N/A	N/A	-20.29%	-19.49%	5/2/2025 (Estimated)
IMCR Immunocore	-$55.29M	-$1.02	N/A	N/A	N/A	-15.87%	-12.84%	-5.09%	5/6/2025 (Estimated)
NTLA Intellia Therapeutics	-$481.19M	-$5.25	N/A	N/A	N/A	N/A	-49.34%	-40.27%	5/8/2025 (Estimated)

Latest IMCR, GHRS, and NTLA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/27/2025	Q4 2024	GHRS GH Research	-$0.23	-$0.17	+$0.06	-$0.17	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GHRS GH Research	N/A	15.83	15.83
IMCR Immunocore	1.03	3.78	3.76
NTLA Intellia Therapeutics	N/A	6.73	6.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GHRS GH Research	56.90%
IMCR Immunocore	84.50%
NTLA Intellia Therapeutics	88.77%

Insider Ownership

Company	Insider Ownership
GHRS GH Research	41.60%
IMCR Immunocore	9.10%
NTLA Intellia Therapeutics	3.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GHRS GH Research	10	52.03 million	30.38 million	Optionable
IMCR Immunocore	320	50.03 million	45.48 million	Optionable
NTLA Intellia Therapeutics	600	103.52 million	98.59 million	Optionable

IMCR, GHRS, and NTLA Headlines

Recent News About These Companies

Class Action Filed Against Intellia Therapeutics, Inc. (NTLA) - April 14, 2025 Deadline to Join - Contact Levi & Korsinsky

April 1 at 7:25 AM | accessnewswire.com

NTLA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Intellia Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!

April 1 at 7:00 AM | accessnewswire.com

Shareholders that lost money on Intellia Therapeutics, Inc.(NTLA) should contact Levi & Korsinsky about pending Class Action - NTLA

April 1 at 5:45 AM | prnewswire.com

Investors who lost money on Intellia Therapeutics, Inc.(NTLA) should contact Levi & Korsinsky about pending Class Action - NTLA

March 31 at 8:00 PM | accessnewswire.com

NTLA LAWSUIT ALERT: Levi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

March 31 at 6:30 PM | accessnewswire.com

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA

March 31 at 6:00 PM | accessnewswire.com

Levi & Korsinsky Reminds Intellia Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLA

March 31 at 2:30 PM | accessnewswire.com

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLA

March 31 at 1:08 PM | globenewswire.com

Intellia Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - NTLA

March 31 at 1:00 PM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA

March 31 at 12:43 PM | prnewswire.com

Intellia Focuses on Pipeline Development Amid Stiff Competition

March 31 at 11:10 AM | zacks.com

Intellia Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Intellia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLA

March 31 at 7:25 AM | accessnewswire.com

NTLA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Intellia Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!

March 31 at 7:00 AM | accessnewswire.com

Contact The Gross Law Firm by April 14, 2025 Deadline to Join Class Action Against Intellia Therapeutics, Inc.(NTLA)

March 31 at 5:45 AM | prnewswire.com

Levi & Korsinsky Reminds Intellia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLA

March 30 at 12:07 PM | accessnewswire.com

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA

March 30 at 12:00 PM | accessnewswire.com

Shareholders of Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA

March 30 at 11:23 AM | accessnewswire.com

Class Action Filed Against Intellia Therapeutics, Inc. (NTLA) Seeking Recovery for Investors - Contact Levi & Korsinsky

March 30 at 8:40 AM | accessnewswire.com

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Intellia Therapeutics, Inc.(NTLA) Shareholders

March 30 at 7:23 AM | accessnewswire.com

NTLA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Intellia Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!

March 30 at 7:00 AM | accessnewswire.com

IQ EQ FUND MANAGEMENT IRELAND Ltd Has $637,000 Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

March 30 at 5:25 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCR, GHRS, and NTLA Company Descriptions

GH Research NASDAQ:GHRS

$10.94 -0.09 (-0.81%)

As of 10:04 AM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Immunocore NASDAQ:IMCR

$29.06 -0.61 (-2.04%)

As of 10:02 AM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Intellia Therapeutics NASDAQ:NTLA

$6.89 -0.22 (-3.09%)

As of 10:04 AM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time